KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Retained Earnings (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Retained Earnings data on record, last reported at -$7.5 million in Q4 2025.

  • For Q4 2025, Retained Earnings rose 96.47% year-over-year to -$7.5 million; the TTM value through Dec 2025 reached -$7.5 million, up 96.47%, while the annual FY2025 figure was -$7.5 million, 96.47% up from the prior year.
  • Retained Earnings reached -$7.5 million in Q4 2025 per EBS's latest filing, roughly flat from -$7.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $957.8 million in Q4 2021 and bottomed at -$212.4 million in Q4 2024.
  • Average Retained Earnings over 5 years is $223.4 million, with a median of -$5.5 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: skyrocketed 3885.77% in 2021, then plummeted 2525.45% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $957.8 million in 2021, then crashed by 99.68% to $3.1 million in 2022, then tumbled by 803.23% to -$21.8 million in 2023, then crashed by 874.31% to -$212.4 million in 2024, then skyrocketed by 96.47% to -$7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$7.5 million in Q4 2025, -$7.5 million in Q3 2025, and -$8.1 million in Q2 2025.